Relief Therapeutics has sold its rights for GOLIKE outside the U.S. to Nutrisens to refocus on R&D and operational efficiency.

Information on the Target

Relief Therapeutics Holding SA is a biopharmaceutical company based in Geneva, Switzerland, that specializes in developing innovative treatment options for rare and unmet medical needs. The company focuses on specialty diseases, with an emphasis on rare skin conditions, metabolic disorders, and respiratory diseases. Relief has recently made a strategic shift, selling its intellectual property and commercialization rights for the GOLIKE product line outside of the United States to Nutrisens, a recognized leader in clinical nutrition solutions.

The GOLIKE product line includes Foods for Special Medical Purposes (FSMPs) designed to closely mimic the physiological absorption of amino acids in natural proteins. GOLIKE addresses dietary management challenges, particularly for individuals with conditions like phenylketonuria, by providing a more palatable alternative to conventional amino acid supplements. Under the agreement, Nutrisens will oversee the marketing and sales of GOLIKE in European markets, allowing Relief to concentrate on research and development.

Industry Overview in Switzerland

The biopharmaceutical industry in Switzerland is recognized as one of the most innovative and efficient globally, playing a pivotal role in healthcare advancements. This sector benefits from a well-established regulatory framework, high investment in research and develop